Literature DB >> 17300800

Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins.

Susumu Sakata1, Djamel Lebeche, Naoya Sakata, Yuri Sakata, Elie R Chemaly, Li Fan Liang, Tsuyoshi Tsuji, Yoshiaki Takewa, Federica del Monte, Richard Peluso, Krisztina Zsebo, Dongtak Jeong, Woo Jin Park, Yoshiaki Kawase, Roger J Hajjar.   

Abstract

The aim of this study was to examine whether short- and long-term gene transfer of Ca(2+) handling proteins restore left ventricular (LV) mechanoenergetics in aortic banding-induced failing hearts. Aortic-banded rats received recombinant adenoviruses carrying sarcoplasmic reticulum Ca(2+)-ATPase (SERCA2a) (Banding+SERCA), parvalbumin (Banding+Parv) or beta-galactosidase (Banding+betagal), or an adeno-associated virus carrying SERCA2a (Banding+AAV.SERCA) by a catheter-based technique. LV mechanoenergetic function was measured in cross-circulated hearts. "Banding", "Banding+betagal" and "Banding+saline" groups showed lower end-systolic pressure at 0.1 ml intraballoon water (ESP(0.1)), higher end-diastolic pressure at 0.1 ml intraballoon water (EDP(0.1)) and slower LV relaxation rate, compared with "Normal" and "Sham". However, "Banding+SERCA" and "Banding+Parv" showed high ESP(0.1), low EDP(0.1) and fast LV relaxation rate. In "Banding", "Banding+betagal" and "Banding+saline", slope of relation between cardiac oxygen consumption and systolic pressure-volume area, O(2) cost of total mechanical energy, was twice higher than normal value, whereas slope in "Baning+SERCA" and "Banding+Parv" was similar to normal value. Furthermore, O(2) cost of LV contractility in the 3 control banding groups was approximately 3 times higher than normal value, whereas O(2) cost of contractility in "Banding+SERCA", "Banding+AAV.SERCA" and "Banding+Parv" was as low as normal value. Thus, high O(2) costs of total mechanical energy and of LV contractility in failing hearts indicate energy wasting both in chemomechanical energy transduction and in calcium handling. Improved calcium handling by both short- and long-term overexpression of SERCA2a and parvalbumin transforms the inefficient energy utilization into a more efficient state. Therefore enhancement of calcium handling either by resequestration into the SR or by intracellular buffering improves not only mechanical but energetic function in failing hearts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17300800      PMCID: PMC1945057          DOI: 10.1016/j.yjmcc.2007.01.003

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  38 in total

1.  Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure.

Authors:  M I Miyamoto; F del Monte; U Schmidt; T S DiSalvo; Z B Kang; T Matsui; J L Guerrero; J K Gwathmey; A Rosenzweig; R J Hajjar
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

Review 2.  Calcium fluxes involved in control of cardiac myocyte contraction.

Authors:  D M Bers
Journal:  Circ Res       Date:  2000-08-18       Impact factor: 17.367

3.  No dependency of a new index for oxygen cost of left ventricular contractility on heart rates in the blood-perfused excised rat heart.

Authors:  S Sakata; Y Ohga; T Abe; N Tabayashi; S Kobayashi; T Tsuji; H Kohzuki; H Misawa; S Taniguchi; M Takaki
Journal:  Jpn J Physiol       Date:  2001-04

4.  Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase.

Authors:  U Schmidt; F del Monte; M I Miyamoto; T Matsui; J K Gwathmey; A Rosenzweig; R J Hajjar
Journal:  Circulation       Date:  2000-02-22       Impact factor: 29.690

Review 5.  Prospects for gene therapy for heart failure.

Authors:  R J Hajjar; F del Monte; T Matsui; A Rosenzweig
Journal:  Circ Res       Date:  2000-03-31       Impact factor: 17.367

6.  In vivo acceleration of heart relaxation performance by parvalbumin gene delivery.

Authors:  M L Szatkowski; M V Westfall; C A Gomez; P A Wahr; D E Michele; C DelloRusso; I I Turner; K E Hong; F P Albayya; J M Metzger
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

7.  Upregulation of Na(+)/Ca(2+) exchanger expression and function in an arrhythmogenic rabbit model of heart failure.

Authors:  S M Pogwizd; M Qi; W Yuan; A M Samarel; D M Bers
Journal:  Circ Res       Date:  1999-11-26       Impact factor: 17.367

8.  Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a.

Authors:  S E Harding; U Schmidt; T Matsui; Z B Kang; G W Dec; J K Gwathmey; A Rosenzweig; R J Hajjar
Journal:  Circulation       Date:  1999-12-07       Impact factor: 29.690

9.  Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca(2+) leak through ryanodine receptor in heart failure.

Authors:  M Yano; K Ono; T Ohkusa; M Suetsugu; M Kohno; T Hisaoka; S Kobayashi; Y Hisamatsu; T Yamamoto; M Kohno; N Noguchi; S Takasawa; H Okamoto; M Matsuzaki
Journal:  Circulation       Date:  2000-10-24       Impact factor: 29.690

10.  Myofilament calcium regulation in human myocardium.

Authors:  R J Hajjar; R H Schwinger; U Schmidt; C S Kim; D Lebeche; A A Doye; J K Gwathmey
Journal:  Circulation       Date:  2000-04-11       Impact factor: 29.690

View more
  63 in total

Review 1.  Reverse remodeling in heart failure--mechanisms and therapeutic opportunities.

Authors:  Norimichi Koitabashi; David A Kass
Journal:  Nat Rev Cardiol       Date:  2011-12-06       Impact factor: 32.419

Review 2.  Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs.

Authors:  Wolfgang Poller; Madlen Rother; Carsten Skurk; Carmen Scheibenbogen
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 3.  Model-specific selection of molecular targets for heart failure gene therapy.

Authors:  Michael G Katz; Anthony S Fargnoli; Catherine E Tomasulo; Louella A Pritchette; Charles R Bridges
Journal:  J Gene Med       Date:  2011-10       Impact factor: 4.565

Review 4.  Cardiac gene therapy.

Authors:  Antoine H Chaanine; Jill Kalman; Roger J Hajjar
Journal:  Semin Thorac Cardiovasc Surg       Date:  2010

Review 5.  Cardiac gene therapy with SERCA2a: from bench to bedside.

Authors:  Judith K Gwathmey; Alexan I Yerevanian; Roger J Hajjar
Journal:  J Mol Cell Cardiol       Date:  2010-11-18       Impact factor: 5.000

6.  Myocardial twitch duration and the dependence of oxygen consumption on pressure-volume area: experiments and modelling.

Authors:  J-C Han; K Tran; A J Taberner; D P Nickerson; R S Kirton; P M F Nielsen; M-L Ward; M P Nash; E J Crampin; D S Loiselle
Journal:  J Physiol       Date:  2012-05-08       Impact factor: 5.182

Review 7.  Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases.

Authors:  Larissa Lipskaia; Lahouaria Hadri; Jose J Lopez; Roger J Hajjar; Regis Bobe
Journal:  Curr Vasc Pharmacol       Date:  2013-07       Impact factor: 2.719

Review 8.  Cardiac contractility modulation therapy in advanced systolic heart failure.

Authors:  Alexander R Lyon; Michael A Samara; David S Feldman
Journal:  Nat Rev Cardiol       Date:  2013-08-13       Impact factor: 32.419

9.  Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

Authors:  Lennart Suckau; Henry Fechner; Elie Chemaly; Stefanie Krohn; Lahouaria Hadri; Jens Kockskämper; Dirk Westermann; Egbert Bisping; Hung Ly; Xiaomin Wang; Yoshiaki Kawase; Jiqiu Chen; Lifan Liang; Isaac Sipo; Roland Vetter; Stefan Weger; Jens Kurreck; Volker Erdmann; Carsten Tschope; Burkert Pieske; Djamel Lebeche; Heinz-Peter Schultheiss; Roger J Hajjar; Wolfgang C Poller
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

Review 10.  Molecular cardiology in translation: gene, cell and chemical-based experimental therapeutics for the failing heart.

Authors:  Immanuel Turner; Fikru Belema-Bedada; Joshua Martindale; Dewayne Townsend; Wang Wang; Nathan Palpant; So-Chiro Yasuda; Matthew Barnabei; Ekaterina Fomicheva; Joseph M Metzger
Journal:  J Cardiovasc Transl Res       Date:  2008-12       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.